Jonathan Ledermann
乔纳森·莱德曼
MD, FRCP
Emeritus Professor of Medical Oncology医学肿瘤学荣誉教授
👥Biography 个人简介
Pioneer of PARP inhibitor research in ovarian cancer and principal investigator of the landmark ICON6 and STUDY 19 trials. His work established olaparib maintenance therapy as a transformative approach for BRCA-mutated ovarian cancer worldwide.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
PARP Inhibitor Development
Led STUDY 19, the first randomized trial demonstrating olaparib maintenance benefit in platinum-sensitive relapsed ovarian cancer, opening a new treatment era.
ICON6 Trial
Principal investigator of ICON6, a pivotal phase III trial evaluating cediranib with chemotherapy in platinum-sensitive relapsed ovarian cancer.
Biomarker-Driven Therapy
Championed BRCA mutation testing as a predictive biomarker for PARP inhibitor response, influencing global treatment guidelines.
Representative Works 代表性著作
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer (STUDY 19)
New England Journal of Medicine (2012)
Landmark RCT establishing olaparib maintenance benefit and identifying BRCA mutation as key predictive biomarker.
Cediranib maleate in platinum-sensitive relapsed ovarian cancer (ICON6)
The Lancet (2015)
Demonstrated cediranib with chemotherapy improved progression-free survival in relapsed platinum-sensitive ovarian cancer.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Bradley J. Monk
University of Arizona / HonorHealth
Kathleen N. Moore
Stephenson Cancer Center, University of Oklahoma
Ana Oaknin
Vall d'Hebron University Hospital
Shannon Neville Westin
The University of Texas MD Anderson Cancer Center
关注 乔纳森·莱德曼 的研究动态
Follow Jonathan Ledermann's research updates
留下邮箱，当我们发布与 Jonathan Ledermann（University College London）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment